Weighted Average Number of Shares Outstanding, Basic of Theravance Biopharma, Inc. from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Theravance Biopharma, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • Theravance Biopharma, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 30 Sep 2025 was 50,520,000, a 3% increase year-over-year.
  • Theravance Biopharma, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 48,847,000, a 12% decline from 2023.
  • Theravance Biopharma, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 55,303,000, a 25% decline from 2022.
  • Theravance Biopharma, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 73,591,000, a 5.9% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Theravance Biopharma, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 50,520,000 +1,482,000 +3% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 50,177,000 +1,430,000 +2.9% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 49,706,000 +1,423,000 +2.9% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 48,847,000 -6,456,000 -12% 01 Oct 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
Q3 2024 49,038,000 -3,323,000 -6.3% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 48,747,000 -7,935,000 -14% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 48,283,000 -14,651,000 -23% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 55,303,000 -18,288,000 -25% 01 Oct 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
Q3 2023 52,361,000 -23,154,000 -31% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 56,682,000 -19,588,000 -26% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 62,934,000 -12,313,000 -16% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 73,591,000 +4,130,000 +5.9% 01 Oct 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
Q3 2022 75,515,000 +1,941,000 +2.6% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 76,270,000 +10,601,000 +16% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 75,247,000 +10,754,000 +17% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 69,461,000 +7,116,000 +11% 01 Oct 2021 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q3 2021 73,574,000 +10,271,000 +16% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 65,669,000 +2,394,000 +3.8% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 64,493,000 +4,417,000 +7.4% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 62,345,000 +6,735,000 +12% 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
Q3 2020 63,303,000 +6,613,000 +12% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 63,275,000 +6,868,000 +12% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 60,076,000 +4,258,000 +7.6% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 55,610,000 01 Oct 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
Q3 2019 56,690,000 +1,460,000 +2.6% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 56,407,000 +1,449,000 +2.6% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 55,818,000 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q3 2018 55,230,000 01 Jul 2018 30 Sep 2018 10-Q 08 Nov 2019 2019 Q3
Q2 2018 54,958,000 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019 2019 Q2

Theravance Biopharma, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 48,847,000 -6,456,000 -12% 01 Jan 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
2023 55,303,000 -18,288,000 -25% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
2022 73,591,000 +4,130,000 +5.9% 01 Jan 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
2021 69,461,000 +7,116,000 +11% 01 Jan 2021 31 Dec 2021 10-K 01 Mar 2023 2022 FY
2020 62,345,000 +6,735,000 +12% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 55,610,000 +534,000 +0.97% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 55,076,000 +1,373,000 +2.6% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 53,703,000 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.